Phosphate and FGF23 in early CKD: On how to tackle an invisible foe

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2430-2432

  Ketteler, Markus ^a   Petermann, Arndt T ^a  

^a KLINIKUM COBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; SEVELAMER; VITAMIN D;

ARTICLE; BIOCHEMISTRY; BONE DISEASE; CHRONIC KIDNEY DISEASE; CORONARY ARTERY CALCIFICATION; DIET RESTRICTION; DISEASE MODEL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; NONHUMAN; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PHOSPHATE BALANCE; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; PHOSPHORUS;

EID: 79961056838     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr344     Document Type: Article

References (11)

1. Isakova T, Wolf MS. FGF23 or PTH: which comes first in CKD? Kidney Int 2010;78:947-949
2. Wolf MS. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010;21:1427-1435
3. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-S130
4. Prié D, Ureña Torres P, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009;75:882-889
5. Koiwa F, Kazama JJ, Tokumoto A et al. ROD21 Clinical Research Group. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9:336-339 (Pubitemid 41800805)
6. Nagano N, Miyata S, Abe M et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006;69:531-537 (Pubitemid 43164446)
7. Gonzalez-Parra E, Gonzalez-Casaus ML, Galán A et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011
8. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5:286-289
9. Isakova T, Gutiérrez OM, Smith K et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011;26:584-591
10. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008;19:615-623 (Pubitemid 351355405)
11. Block GA, Persky MS, Ketteler M et al. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: a new paradigm for clinical outcomes studies in nephrology. Hemodial Int 2009;13:360-362